Séamus Sreenan

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Troglitazone action is independent of adipose tissue.

Charles Burant, Séamus Sreenan, Ken‐ichi Hirano et al. · Journal of Clinical Investigation · 1997 · 338 citations · Full text

Brown Fat, Metabolic Remodeling, Insulin Signaling +16

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Alan J. Garber, Allen B. King, Stefano Del Prato et al. · The Lancet · 2012 · 323 citations

Diabetes Management, Insulin Degludec, Diabetes +7

Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice.

Marco Pontoglio, Séamus Sreenan, William Pugh et al. · Journal of Clinical Investigation · 1998 · 322 citations · Full text

Genetics, Insulin Signaling, Metabolic Syndrome +18

Visualizing Superoxide Production in Normal and Diabetic Rat Islets of Langerhans

Vytautas P. Bindokas, Andrey V. Kuznetsov, Séamus Sreenan et al. · Journal of Biological Chemistry · 2003 · 235 citations · Full text